The Latest Cardiac and Vascular News
SANTA CLARA, Calif., Aug. 05, 2019 (GLOBE NEWSWIRE) — Shockwave Medical, Inc. (Nasdaq: SWAV), a pioneer in the development and commercialization of Intravascular Lithotripsy (IVL) to treat complex calcified cardiovascular disease, today reported financial results for the three months ended June 30, 2019. Recent Highlights Recognized revenue of $10.0 million […]
SANTA CLARA, Calif., June 10, 2019 (GLOBE NEWSWIRE) — Shockwave Medical, Inc. (NASDAQ: SWAV), a pioneer in the development and commercialization of Intravascular Lithotripsy (IVL) to treat complex calcified cardiovascular disease, announced today that the Company has appointed Hajime Tada as General Counsel. From 2017 to 2019, Mr. Tada was […]
SANTA CLARA, Calif., May 15, 2019 (GLOBE NEWSWIRE) — Shockwave Medical, Inc. (NASDAQ: SWAV), a pioneer in the development and commercialization of Intravascular Lithotripsy (IVL) to treat complex calcified cardiovascular disease, announced today that the Company has appointed Keith D. Dawkins, M.D. as Chief Medical Officer. “Given the challenges associated […]
SANTA CLARA, Calif., April 03, 2019 (GLOBE NEWSWIRE) — Shockwave Medical, Inc. (NASDAQ: SWAV), a pioneer in the development and commercialization of Intravascular Lithotripsy (IVL) to treat complex calcified cardiovascular disease, has completed enrollment of its DISRUPT CAD II study, a regulatory-required European post-market registry of coronary IVL. IVL is […]
SUWANEE, GA, April 02, 2019 (GLOBE NEWSWIRE) — via NEWMEDIAWIRE — SANUWAVE Health, Inc. (OTCQB: SNWV), an emerging medical technology company focused on the development and commercialization of noninvasive, biological response activating devices in regenerative medicine, received United States Patent US 10,238,405 on March 26, 2019 entitled “Blood Vessel Treatment […]
SANTA CLARA, Calif., March 06, 2019 (GLOBE NEWSWIRE) — ShockWave Medical, Inc. (“ShockWave”) today announced the pricing of its initial public offering of 5,700,000 shares of its common stock at a price to the public of $17.00 per share. The shares are expected to begin trading on the Nasdaq Global […]
SANTA CLARA, Calif., Feb. 07, 2019 (GLOBE NEWSWIRE) — Shockwave Medical, a pioneer in the development and commercialization of Intravascular Lithotripsy to treat complex calcified cardiovascular disease, today announced that Laura Francis has joined its Board of Directors and will serve as Chairperson of Shockwave’s Audit Committee. Ms. Francis currently […]
SANTA CLARA, Calif., Jan. 14, 2019 (GLOBE NEWSWIRE) — Shockwave Medical, Inc., a pioneer in the development and commercialization of Intravascular Lithotripsy (IVL) to treat complex calcified cardiovascular disease, has initiated its U.S. Food and Drug Administration (FDA) Investigational Device Exemption (IDE) study – DISRUPT CAD III – for the […]
SANTA CLARA, Calif., Jan. 04, 2019 (GLOBE NEWSWIRE) — Shockwave Medical (“Shockwave”), a pioneer in the development and commercialization of intravascular lithotripsy to treat complex calcified cardiovascular disease, today announced that its Board of Directors has appointed Ray Larkin Jr. to join its Board of Directors and to serve as […]
SANTA CLARA, Calif., Dec. 11, 2018 (GLOBE NEWSWIRE) — Shockwave Medical, a pioneer in the development and commercialization of intravascular lithotripsy to treat complex calcified cardiovascular disease, today announced an investment and collaboration agreement with Abiomed, Inc. As outlined by the agreement, Abiomed will invest $15 million in Shockwave and […]
